Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Nvidia Develops New Location-Verification Technology for AI Chips 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Pfizer has entered into a licensing agreement worth up to $6 billion with Chinese biopharmaceutical firm 3SBio Inc, aiming to advance a promising cancer treatment currently in clinical trials. The collaboration underscores Pfizer’s growing interest in oncology and its strategic push into the Asian pharmaceutical market.
Under the agreement, 3SBio will take charge of developing, manufacturing, and commercializing the investigational drug in China. The compound, still in trial phases, is designed to treat various cancers and tumors, though specific indications have not been disclosed. Pfizer retains rights outside of China and will receive milestone payments and royalties based on development progress and commercial performance.
This partnership highlights a trend of Western pharmaceutical giants teaming up with Chinese biotech firms to accelerate access to cutting-edge therapies in one of the world’s fastest-growing healthcare markets. For Pfizer, the deal not only strengthens its oncology portfolio but also aligns with its broader strategy of expanding its presence in emerging markets.
The deal’s structure includes upfront and milestone payments that could total $6 billion, signaling strong confidence in the drug’s potential. It also reflects Pfizer’s continued investment in targeted cancer therapies and biologics, which have become critical areas of growth amid increasing global demand.
By collaborating with 3SBio, a company with established R&D and commercial infrastructure in China, Pfizer leverages local expertise to navigate regulatory pathways and bring advanced treatments to Chinese patients faster. For 3SBio, the partnership provides access to innovative science and strengthens its oncology pipeline.
This move is part of Pfizer’s ongoing strategy to forge global alliances that accelerate innovation and deliver next-generation cancer treatments worldwide. With the global oncology market projected to surpass $500 billion by 2030, such partnerships are key to staying competitive and impactful in the pharmaceutical space.
